DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

30 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

08 Aug 2023 16:01:27 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

20 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

10 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

27 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

22 Feb 2023 16:33:24 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

15 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

25 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

09 Jan 2023 08:00:44 By Nasdaq GlobeNewswire

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

05 Dec 2022 07:00:41 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

03 Nov 2022 16:01:44 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN

01 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

24 Oct 2022 16:30:04 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

19 Oct 2022 21:19:42 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock

18 Oct 2022 16:40:50 By Nasdaq GlobeNewswire

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

03 Oct 2022 08:00:39 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

31 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

08 Aug 2022 16:01:01 By Nasdaq GlobeNewswire

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

31 May 2022 08:00:02 By Nasdaq GlobeNewswire